AlphAIAlphAI — Financial news for AI agents
Zacks CommentaryOCT 233 min read$CARE

Compared to Estimates, Carter Bankshares (CARE) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Carter Bankshares (CARE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 23, 2025, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Compared to Estimates, Carter Bankshares (CARE) Q3 Earnings: A Look at Key Metrics — source image
Source · www.zacks.com
Decision brief

The 30-second read

$CARENeutralMed
01

Why it matters

The earnings were in line with estimates, suggesting stability but limited growth potential.

02

Market read

Moderate relevance for investors focusing on regional banks; limited impact on broader markets.

03

What to watch

Potential impacts of interest rate changes or regulatory developments not accounted for in current analysis.

Timing: short-term (next 1-2 weeks)

Background

Carter Bankshares reported Q3 2025 earnings, providing insight into regional banking sector health.

Company-level read

Ticker impact

$CARENeutralMedium confidence
Context

Recent quarterly earnings report compared to Wall Street estimates and previous year.

Expected impact

Minimal short-term price movement expected; potential for slight volatility if future earnings diverge significantly from estimates.

Evidence & confidence

The data shows performance aligned with expectations, but market reactions depend on broader economic factors and future guidance.

Market effects

Sector

Banking and regional financial services sectors may experience minor volatility based on earnings performance.

Regional

Limited regional impact; primarily affects investors in the bank's local markets.

Global

Negligible

Counterpoint

What could challenge this read

If upcoming economic data indicates a slowdown, the bank's performance might underperform expectations, presenting a buying opportunity at lower prices.

Key entities

  • Company
    Carter Bankshares

    Regional bank providing financial services.

Read at source← All news

Related articles

JUL 23
$CAREMed

Carter Bankshares, Inc. (CARE): Results of Operations and Financial Condition

Carter Bankshares, Inc. (CARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 care-2q26_ex991xer.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE – July 23, 2026 Carter Bankshares, Inc. Announces Second Quarter 2026 Financial Results Martinsville, VA, July 23, 2026 – Carter Bankshares, Inc. (the “Company”) (NASDAQ:CARE), the holding compan

SEC EDGAR 8-K6 min
SEP 29
$RCLMed

Is Royal Caribbean Cruises (RCL) Cheap On Analyst Upgrades And The Sandals Deal?

Royal Caribbean Cruises (RCL) has been upgraded by Bank of America and Deutsche Bank, citing a recent pullback and a Sandals Resorts partnership. The stock is down 13% in the past month and 24% in the past quarter, but has a 3-year total shareholder return of over 100%. Analysts estimate a fair value of $346.92, suggesting undervaluation. Revenue growth is expected from enhanced guest experiences and loyalty programs, but risks include consumer travel budgets and fuel costs.

simplywall.st2 min
SEP 29
$TMed

Can AT&T (T) Turn Higher ARPU Into Bigger Cash Flow?

BNP Paribas upgraded AT&T (T) to Outperform, raising its price target to $30. The firm cited a more rational U.S. wireless market and expected ARPU growth, which could boost revenue, EBITDA, and free cash flow. AT&T reported Q2 2026 revenues of $31.6B, EBITDA of $12.3B, and free cash flow of $4.7B, with plans to return $45B to shareholders by 2028. Concerns include high debt and legacy service declines.

insidermonkey.com2 min
SEP 28
$GILDMed

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

Gilead Sciences (GILD) expanded its royalty-free licensing for lenacapavir to include a once-yearly HIV PrEP formulation, covering 120 lower-income countries. The move aims to accelerate manufacturing and secure market dominance. Gilead's HIV sales grew 12% YoY to $5.7B in Q2 2026, but the company reported losses due to acquisition-related R&D charges.

insidermonkey.com3 min
SEP 28
$GSMed

Goldman Sachs CEO Transition: John Waldron Set to Succeed David

Goldman Sachs (GS) may see a leadership change, with John Waldron potentially replacing David Solomon as CEO. Solomon could become Executive Chairman. GS has a 2.03% dividend yield, a GF Score of 83, and is seen as 9.8% overvalued. Insider selling has been significant, with $1.09M in sales over three months. The firm has a market cap of $266.79B and operates in investment banking, asset management, and transaction banking.

gurufocus.com2 min